Vaccine-induced immune thrombotic thrombocytopenia with atypical vein thrombosis: Implications for clinical practice

Abstract

Objectives

Vaccine-induced immune thrombotic thrombocytopenia (VITT) is a new and rare syndrome resulting from the largest vaccination campaign against SARS-CoV-2 in the history of mankind. The aim of this review is to clarify underlying mechanisms, pathology, diagnosis, and therapy, with the related clinical implications.

Methods

We performed a comprehensive literature review in order to collect the clinical and treatment data about patients suffering from VITT. PubMed, Ovid Medline, Ovid EMBASE, Scopus, and Web of Science were screened regarding patients who developed VITT. Last search was launched on June 30^th 2021.

Results

Abdominal and/or neurological symptoms develop between 5 and 20 days after vaccine administration and do not involve the lower extremities. VITT is suspected if the platelet count is lower than 100.000/mm³ and D-dimer is higher than the age-adjusted range. Medical treatment is mainly based on intravenous immunoglobulins, corticosteroids, and anticoagulant drugs with a short plasma half-life, but the complete avoidance of low molecular weight heparin is recommended. Endovascular treatment and/or decompressive craniectomy might be an option in a minority of cases.

Conclusion

Due to widespread vaccination concerns, the vascular specialist and phlebologist are increasingly consulted to prevent or diagnose VITT. The latter has peculiar and completely different localizations, symptoms, and treatment compared to the common pictures of venous thrombosis.

Keywords

Vaccine-induced immune thrombotic thrombocytopenia SARS-CoV-2 Vaxzevria Ad.26. COV2.S cerebral venous sinus thrombosis splanchnic vein thrombosis

Get full access to this article

View all access options for this article.

References

Muir

K-L

Kallam

Koepsell

, et al. Thrombotic thrombocytopenia after Ad26.COV2.S vaccination. N Engl J Med 2021; 384: 1964–1965.

Scully

Singh

Lown

, et al. Pathologic antibodies to platelet factor 4 after ChAdOx1 nCoV-19 Vaccination. N Engl J Med 2021; 384(23): 2202–2211. DOI: 10.1056/NEJMoa2105385.

Greinacher

Thiele

Warkentin

, et al. Thrombotic thrombocytopenia after ChAdOx1 nCov-19 vaccination. N Engl J Med 2021; 384: 2092–2101.

Schultz

Sørvoll

Michelsen

, et al. Thrombosis and thrombocytopenia after ChAdOx1 nCoV-19 vaccination. New Engl J Med 2021; 384: 2124–2130.

See

Lale

, et al. US case reports of cerebral venous sinus thrombosis with thrombocytopenia after Ad26.COV2.S vaccination, March 2 to April 21, 2021. JAMA 2021; 30: e217517.

Shay

Gee

, et al. Safety monitoring of the Janssen (Johnson & Johnson) COVID-19 vaccine - United States, March-April 2021. MMWR Morb Mortal Wkly Rep 2021; 70: 680–684.

Dias

Soares-dos-Reis

Meira

, et al. Cerebral venous thrombosis after BNT162b2 mRNA SARS–CoV2 vaccine. J Stroke Cerebrovasc Dis 2021; 30: 105906.

Cari

Fiore

Naghavi Alhosseini

, et al. Blood clots and bleeding events following BNT162b2 and ChAdOx1 nCoV-19 vaccine: An analysis of European data. J Autoimmun 2021; 122: 102685.

Ferro

JM.

Bousser

M-G

Canhão

, et al. European stroke organization guideline for the diagnosis and treatment of cerebral venous thrombosis - endorsed by the European academy of neurology. Eur Stroke J 2017; 2: 195–221.

10.

Riva

Ageno

. Clinical manifestations and imaging tools in the diagnosis of splanchnic and cerebral vein thromboses. Thromb Res 2018; 163: 252–259.

11.

Northup

Garcia‐Pagan

Garcia‐Tsao

, et al. Vascular liver disorders, portal vein thrombosis, and procedural bleeding in patients with liver disease: 2020 practice guidance by the American association for the study of liver diseases. Hepatology 2021; 73: 366–413.

12.

Greinacher

Farner

Kroll

, et al. Clinical features of heparin-induced thrombocytopenia including risk factors for thrombosis. a retrospective analysis of 408 patients. Thromb Haemost 2005; 94: 132–135.

13.

Platton

Bartlett

MacCallum

, et al. Evaluation of laboratory assays for anti-platelet factor 4 antibodies after ChAdOx1 nCOV-19 vaccination. J Thromb Haemost 2021; 19: 2007–2013.

14.

Favaloro

Mohammed

Donikian

, et al. A multicentre assessment of contemporary laboratory assays for heparin induced thrombocytopenia. Pathology 2021; 53: 247–256.

15.

Gresele

Marietta

Ageno

, et al. Management of cerebral and splanchnic vein thrombosis associated with thrombocytopenia in subjects previously vaccinated with Vaxzevria (AstraZeneca): a position statement from the Italian society for the study of haemostasis and thrombosis (SISET). Blood Transfus 2021; 19: 281–283.

16.

Oldenburg

Klamroth

Langer

, et al. Diagnosis and management of vaccine-related thrombosis following AstraZeneca COVID-19 vaccination: guidance statement from the GTH. Hamostaseologie 2021; 41: 184–189.

17.

Gertsch

Matthews

Lerut

. Acute thrombosis of the splanchnic veins. Arch Surg 1993; 128: 341–345.

18.

Kim

Patra

Khan

, et al. Transhepatic catheter-directed thrombectomy and thrombolysis of acute superior mesenteric venous thrombosis. J Vasc Interv Radiol 2005; 16: 1685–1691.

19.

Hollingshead

Burke

Mauro

, et al. Transcatheter thrombolytic therapy for acute mesenteric and portal vein thrombosis. J Vasc Interv Radiol 2005; 16: 651–661.

20.

Ferro

Rossi

Bovio

, et al. Transjugular intrahepatic portosystemic shunt, mechanical aspiration thrombectomy, and direct thrombolysis in the treatment of acute portal and superior mesenteric vein thrombosis. Cardiovasc Intervent Radiol 2007; 30: 1070–1074.

21.

Velat

Skowlund

Waters

, et al. Direct thrombectomy using the penumbra thromboaspiration catheter for the treatment of cerebral venous sinus thrombosis. World Neurosurg 2012; 77: 591.e15–591.e18.

22.

Saposnik

Barinagarrementeria

Brown

Jr , et al. Diagnosis and management of cerebral venous thrombosis: a statement for healthcare professionals from the American heart association/american stroke association. Stroke 2011; 42: 1158–1192.

23.

Coutinho

Zuurbier

Bousser

M-G

, et al. Effect of endovascular treatment with medical management vs standard care on severe cerebral venous thrombosis: the TO-ACT randomized clinical trial. JAMA Neurol 2020; 77: 966–973.

24.

Haghighi

Edgell

Cruz-Flores

, et al. Mortality of cerebral venous-sinus thrombosis in a large national sample. Stroke 2012; 43: 262–264.

25.

Avanali

Gopalakrishnan

Devi

, et al. Role of decompressive craniectomy in the management of cerebral venous sinus thrombosis. Front Neurol 2019; 10: 511.

26.

Ferro

Bousser

M-G

Canhão

, et al. European stroke organization guideline for the diagnosis and treatment of cerebral venous thrombosis - endorsed by the European academy of neurology. Eur Stroke J 2017; 2: 195–221.

27.

Gessler

Schmitz

Dubinski

, et al. Neurosurgical considerations regarding decompressive craniectomy for intracerebral hemorrhage after SARS-CoV-2-vaccination in vaccine induced thrombotic thrombocytopenia-VITT. J Clin Med 2021; 10: 2777.

28.

Sessa

Salerno

Pomara

. Autopsy tool in unknown diseases: the experience with coronaviruses (SARS-CoV, MERS-CoV, SARS-CoV-2). Medicina 2021; 57: 309.

29.

Pomara

Sessa

Ciaccio

, et al. Post-mortem findings in vaccine-induced thrombotic thombocytopenia. Haematologica 2021; 106: 2291–2293.

30.

Pomara

Sessa

Ciaccio

, et al. COVID-19 vaccine and death: causality algorithm according to the WHO eligibility diagnosis. Diagnostics 2021; 11: 955.

31.

Edler

Klein

Schröder

, et al. Deaths associated with newly launched SARS-CoV-2 vaccination (Comirnaty^®). Leg Med (Tokyo) 2021; 51: 101895.

32.

Althaus

Möller

Uzun

, et al. Antibody-mediated procoagulant platelets in SARS-CoV-2- vaccination associated immune thrombotic thrombocytopenia. Haematologica 2021; 106: 2170–2179.

33.

Bjørnstad-Tuveng

Rudjord

Anker

. Fatal cerebral haemorrhage after COVID-19 vaccine. Tidsskr Nor Laegeforen 2021; 141(8): 1–6, DOI:10.4045/tidsskr.21.0312.

Supplementary Material

Please find the following supplemental material available below.

For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.

For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.

0.00 MB

0.16 MB